Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-09-21

Clinical Trial Update: A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 study evaluating two doses of dulaglutide (LY2189265) in Japanese patients with Type 2 diabetes, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dulaglutide (dulaglutide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2023-09-21